Sanofi (SNY) Earns Hold Rating from Jefferies Group
Other equities research analysts also recently issued research reports about the stock. Zacks Investment Research downgraded shares of Sanofi from a buy rating to a hold rating in a research report on Monday, June 6th. Citigroup Inc. reissued a neutral rating on shares of Sanofi in a research report on Tuesday, June 28th. TheStreet raised shares of Sanofi from a hold rating to a buy rating in a research report on Wednesday, July 27th. BNP Paribas raised shares of Sanofi from an underperform rating to a neutral rating in a research report on Tuesday, September 13th. Finally, Berenberg Bank reissued a hold rating and set a $93.00 price target on shares of Sanofi in a research report on Monday, August 15th. Three equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and four have given a buy rating to the company’s stock. The company presently has a consensus rating of Hold and an average price target of $60.50.
Shares of Sanofi (NYSE:SNY) opened at 38.43 on Wednesday. Sanofi has a one year low of $37.41 and a one year high of $51.88. The company has a market cap of $98.92 billion, a PE ratio of 21.21 and a beta of 1.01. The firm’s 50-day moving average is $40.00 and its 200-day moving average is $40.68.
Several hedge funds and other institutional investors have recently modified their holdings of the company. Bessemer Group Inc. boosted its position in shares of Sanofi by 77.1% in the second quarter. Bessemer Group Inc. now owns 3,445 shares of the company’s stock valued at $144,000 after buying an additional 1,500 shares in the last quarter. Signaturefd LLC boosted its position in shares of Sanofi by 16.4% in the second quarter. Signaturefd LLC now owns 3,480 shares of the company’s stock valued at $146,000 after buying an additional 490 shares in the last quarter. JFS Wealth Advisors LLC boosted its position in shares of Sanofi by 3.5% in the second quarter. JFS Wealth Advisors LLC now owns 3,961 shares of the company’s stock valued at $166,000 after buying an additional 134 shares in the last quarter. BlackRock Institutional Trust Company N.A. acquired a new position in shares of Sanofi during the first quarter valued at $175,000. Finally, Bradley Foster & Sargent Inc. CT acquired a new position in shares of Sanofi during the second quarter valued at $205,000. Institutional investors and hedge funds own 9.42% of the company’s stock.
Sanofi Company Profile
Sanofi SA is a healthcare company focused on patient needs and engaged in the research, development, manufacture and marketing of healthcare products. The Company is organized around three principal activities: Pharmaceuticals, Human Vaccines via Sanofi Pasteur, and Animal Health via Merial. The Company invests in emerging markets, diabetes solutions, vaccines, consumer health care, animal health, genzyme and other products.
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with Analyst Ratings Network's FREE daily email newsletter.